GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » Beneish M-Score

Northwest Biotherapeutics (Northwest Biotherapeutics) Beneish M-Score : -3.32 (As of Apr. 29, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.32 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Northwest Biotherapeutics's Beneish M-Score or its related term are showing as below:

NWBO' s Beneish M-Score Range Over the Past 10 Years
Min: -13.44   Med: -4.85   Max: 47.01
Current: -3.32

During the past 13 years, the highest Beneish M-Score of Northwest Biotherapeutics was 47.01. The lowest was -13.44. And the median was -4.85.


Northwest Biotherapeutics Beneish M-Score Historical Data

The historical data trend for Northwest Biotherapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Beneish M-Score Chart

Northwest Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 -13.44 -4.74 -4.96 -3.32

Northwest Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.96 -4.69 -4.73 -4.14 -3.32

Competitive Comparison of Northwest Biotherapeutics's Beneish M-Score

For the Biotechnology subindustry, Northwest Biotherapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Beneish M-Score falls into.



Northwest Biotherapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Northwest Biotherapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 1.132+0.892 * 1.148+0.115 * 0.9499
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.776+4.679 * -0.255231-0.327 * 0.5768
=-3.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0.445 + 0.406 + 0.201 + 0.88 = $1.93 Mil.
Gross Profit was 0.445 + 0.406 + 0.201 + 0.88 = $1.93 Mil.
Total Current Assets was $4.13 Mil.
Total Assets was $27.87 Mil.
Property, Plant and Equipment(Net PPE) was $21.46 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.73 Mil.
Selling, General, & Admin. Expense(SGA) was $29.71 Mil.
Total Current Liabilities was $45.20 Mil.
Long-Term Debt & Capital Lease Obligation was $24.77 Mil.
Net Income was -18.919 + -18.58 + -14.448 + -10.652 = $-62.60 Mil.
Non Operating Income was -2.535 + -3.085 + 0.431 + 3.339 = $-1.85 Mil.
Cash Flow from Operations was -16.958 + -13.919 + -11.521 + -11.239 = $-53.64 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0.597 + 0.206 + 0.477 + 0.403 = $1.68 Mil.
Gross Profit was 0.597 + 0.206 + 0.477 + 0.403 = $1.68 Mil.
Total Current Assets was $9.43 Mil.
Total Assets was $31.32 Mil.
Property, Plant and Equipment(Net PPE) was $19.64 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.50 Mil.
Selling, General, & Admin. Expense(SGA) was $33.35 Mil.
Total Current Liabilities was $126.01 Mil.
Long-Term Debt & Capital Lease Obligation was $10.36 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 1.932) / (0 / 1.683)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.683 / 1.683) / (1.932 / 1.932)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4.125 + 21.461) / 27.865) / (1 - (9.425 + 19.635) / 31.323)
=0.081787 / 0.072247
=1.132

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.932 / 1.683
=1.148

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.5 / (1.5 + 19.635)) / (1.733 / (1.733 + 21.461))
=0.070972 / 0.074718
=0.9499

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(29.71 / 1.932) / (33.353 / 1.683)
=15.377847 / 19.817588
=0.776

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((24.766 + 45.204) / 27.865) / ((10.361 + 126.005) / 31.323)
=2.511035 / 4.353542
=0.5768

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-62.599 - -1.85 - -53.637) / 27.865
=-0.255231

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Northwest Biotherapeutics has a M-score of -3.32 suggests that the company is unlikely to be a manipulator.


Northwest Biotherapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Northwest Biotherapeutics (Northwest Biotherapeutics) Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Executives
Navid Malik director 1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch officer: Chief Technical Officer 22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton director, officer: Chief Scientific Officer 22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman officer: See Remarks C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers director, 10 percent owner, officer: President and CEO 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski director C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis officer: See Remarks 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh director WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer director 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp 10 percent owner 27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund 10 percent owner C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc. 10 percent owner 7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer director 10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr. 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814

Northwest Biotherapeutics (Northwest Biotherapeutics) Headlines

From GuruFocus

Northwest Biotherapeutics Announces $15 Million Financing

By PRNewswire PRNewswire 11-29-2021